Data Support Increased Subcutaneous Rituximab Use in Non-Hodgkin Lymphoma

Subcutaneous rituximab showed similar efficacy and safety to intravenous rituximab in non-Hodgkin lymphoma, with lower costs and shorter administration times. Education and training are crucial for increasing subcutaneous rituximab use.